The success of immune checkpoint blockade in patients with a wide variety of malignancies
has changed the treatment paradigm in oncology. However, combination therapies with …

With recent approvals for multiple therapeutic antibodies that block cytotoxic T lymphocyte
associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) in melanoma …

Epigenetic dysregulation is a common feature of most cancers, often occurring directly
through alteration of epigenetic machinery. Over the last several years, a new generation of …

Transposable elements (TEs) are insertional mutagens that contribute greatly to the
plasticity of eukaryotic genomes, influencing the evolution and adaptation of species as well …

The study of tumour-specific antigens (TSAs) as targets for antitumour therapies has
accelerated within the past decade. The most commonly studied class of TSAs are those …

Next-generation sequencing has revealed that more than 50% of human cancers harbour
mutations in enzymes that are involved in chromatin organization. Tumour cells not only are …

Transposable elements are abundant in the human genome, and great strides have been
made in pinpointing variations in these repetitive sequences using whole-genome …

In mice, only the zygotes and blastomeres from 2-cell embryos are authentic totipotent stem
cells (TotiSCs) capable of producing all the differentiated cells in both embryonic and …

Regulatory programs that control the function of stem cells are active in cancer and confer
properties that promote progression and therapy resistance. However, the impact of a stem …

Pathogen-derived nucleic acids are crucial signals for innate immunity. Despite the
structural similarity between those and host nucleic acids, mammalian cells have been able …